BlackRock Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

BlackRock Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$156M	Buy	2,117,536 +453,194	+27%	+$36.9M	0.16%	144
2016 Q3	$145M	Buy	1,664,342 +154,652	+10%	+$14.6M	0.15%	162
2016 Q2	$130M	Sell	1,509,690 -346,298	-19%	-$29.9M	0.13%	173
2016 Q1	$148M	Buy	1,855,988 +4,728	+0.3%	+$428K	0.15%	151
2015 Q4	$233M	Buy	1,851,260 +144,624	+8%	+$17.5M	0.25%	103
2015 Q3	$178M	Sell	1,706,636 -1,519,788	-47%	-$195M	0.19%	126
2015 Q2	$398M	Sell	3,226,424 -182,851	-5%	-$23M	0.41%	63
2015 Q1	$402M	Buy	3,409,275 +306,342	+10%	+$36.7M	0.41%	66
2014 Q4	$369M	Buy	3,102,933 +971,254	+46%	+$109M	0.37%	66
2014 Q3	$239M	Buy	2,131,679 +1,000,568	+88%	+$95.3M	0.24%	107
2014 Q2	$107M	Sell	1,131,111 -309,045	-21%	-$21.7M	0.1%	218
2014 Q1	$102M	Sell	1,440,156 -25,580	-2%	-$2.03M	0.1%	226
2013 Q4	$109M	Sell	1,465,736 -90,322	-6%	-$6.29M	0.1%	210
2013 Q3	$118M	Buy	1,556,058 +743,057	+91%	+$59.1M	0.12%	198
2013 Q2	$65.1M	Buy	+813,001	New	+$59.9M	0.07%	276

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Advisors's VRTX Position: Q4 2016 in Review

BlackRock Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 27% in Q4 2016, buying an estimated $36.9M and bringing the position to 2,117,536 shares worth $156M. The position accounts for 0.16% of the portfolio, ranked #144.

BlackRock Advisors first reported a position in VRTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $402M in Q1 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

BlackRock Advisors held 2,117,536 shares of Vertex Pharmaceuticals worth $156M as of Q4 2016.
BlackRock Advisors bought 453,194 Vertex Pharmaceuticals shares in Q4 2016, an estimated $36.9M.
Vertex Pharmaceuticals made up 0.16% of BlackRock Advisors's portfolio in Q4 2016, its #144 holding.
BlackRock Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Vertex Pharmaceuticals position peaked at $402M in Q1 2015.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.